DECEMBER 3rd, 2020 03:30PM CET
Regulatory Considerations on Imaging Endpoint Procedures in Oncology Trials: a Comparison of China NMPA and FDA Guidelines
In April 2020, The China National Medical Products Administration (NMPA) regulatory agency publicly solicited opinions on the draft guidelines on “Standard and Technical Guidelines for Imaging Endpoint Procedures for Clinical Trials of Anti-tumor Drugs”.
Please join our upcoming webinar: Dr. Yan Liu, Median’s CMO and a member of the expert panel who developed the NMPA guidelines, as well as Mr. Faisel Jobrani, Head of Median QA will provide you with a clear vision based on concrete examples. The webinar will be held in English.